FDA re­jects cit­i­zen pe­ti­tion claim­ing Cas­sa­va ma­nip­u­lat­ed da­ta, but the biotech's woes are not over

Un­der fire from all fronts over al­le­ga­tions of da­ta ma­nip­u­la­tion, Cas­sa­va Sci­ences picked up a small win Thurs­day, but isn’t out of the woods yet on da­ta ma­nip­u­la­tion con­cerns.

The FDA de­nied a cit­i­zen pe­ti­tion from a short sell­er firm ask­ing the agency to in­ves­ti­gate claims that Cas­sa­va fudged da­ta for its Alzheimer’s drug, simu­fil­am. But the reg­u­la­tors on­ly re­buffed the pe­ti­tion on pro­ce­dur­al grounds, with­out ad­dress­ing the ac­cu­sa­tions, say­ing the FDA is not legal­ly al­lowed to ini­ti­ate in­ves­ti­ga­tions based on cit­i­zen pe­ti­tion re­quests.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER